For research use only. Not for therapeutic Use.
S07-1066 is an aldo-keto reductase 1C3 (AKR1C3) inhibitor, synergizing doxorubicin (DOX) cytotoxicity. S07-1066 selectively blocks AKR1C3-mediated reduction of DOX, and reverses the DOX resistance in overexpressing AKR1C3 cells[1].
| Catalog Number | I040892 |
| CAS Number | 876625-29-5 |
| Synonyms | 1-[4-(3,5-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid |
| Molecular Formula | C16H11Cl2FO2 |
| Purity | ≥95% |
| InChI | InChI=1S/C16H11Cl2FO2/c17-11-5-9(6-12(18)8-11)13-2-1-10(7-14(13)19)16(3-4-16)15(20)21/h1-2,5-8H,3-4H2,(H,20,21) |
| InChIKey | DFJGLZRYGZSQOR-UHFFFAOYSA-N |
| SMILES | C1CC1(C2=CC(=C(C=C2)C3=CC(=CC(=C3)Cl)Cl)F)C(=O)O |
| Reference | [1]. He S, et al. Development of Biaryl-Containing Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors for Reversing AKR1C3-Mediated Drug Resistance in Cancer Treatment. J Med Chem. 2023 Jul 6. |
